The erythrocyte antibody-(EA)-rosette method for the demonstration of inhibitory factors binding to the lymphocyte IgG-Fc receptors in the sera of lung cancer patients

B. Fekete, L. Sachno, I. Forrai, A. Pal

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Fc-inhibitory activity was demonstrated by the EA-rosette method in sera of patients with lung cancer. The sera were found to produce a significant rosette inhibition at end concentrations as low as 4%. Results obtained with sera from normal subjects as well as from patients with chronic bronchitis, were significantly different. Mean rosette inhibitory activity was significantly higher in the group of patients with inoperable lung cancer (50 cases) than in the operable group (33 cases). The proportion of patients in whom the difference between their EA-rosette inhibitory activity and the mean value for normal subjects was in excess of +2SD, was 42/50 for the inoperable and 24/33 for the operable group. The EA-rosette inhibition showed the highest frequency in anaplastic carcinoma, followed in order of succession, by adenocellular and planocellular carcinoma, it being rarest in microcellular carcinoma. In survival there was no significant difference between the EA-rosette inhibitors of the inoperable group, while the proportion of patients who were still alive at the time of completion of the assays was found to be lower among the non-inhibitors than among the inhibitors. This may be connected with the high proportion of microcellular type tumour in the negative group (4 out of 9). Successful removal of the tumour was followed by a decline of EA-rosette inhibitory activity in 14 of 17 cases. On the other hand, in 3 inoperable cases the inhibitory activity increased postoperatively.

Original languageEnglish
Pages (from-to)235-243
Number of pages9
JournalActa Medica Academiae Scientiarum Hungaricae
Volume38
Issue number3
Publication statusPublished - 1981

Fingerprint

IgG Receptors
Fc Receptors
Lung Neoplasms
Erythrocytes
Lymphocytes
Antibodies
Serum
Carcinoma
Chronic Bronchitis
Squamous Cell Carcinoma
Neoplasms
Reference Values
Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{8e6db3d4f8e04b6d8f361839cf28598b,
title = "The erythrocyte antibody-(EA)-rosette method for the demonstration of inhibitory factors binding to the lymphocyte IgG-Fc receptors in the sera of lung cancer patients",
abstract = "Fc-inhibitory activity was demonstrated by the EA-rosette method in sera of patients with lung cancer. The sera were found to produce a significant rosette inhibition at end concentrations as low as 4{\%}. Results obtained with sera from normal subjects as well as from patients with chronic bronchitis, were significantly different. Mean rosette inhibitory activity was significantly higher in the group of patients with inoperable lung cancer (50 cases) than in the operable group (33 cases). The proportion of patients in whom the difference between their EA-rosette inhibitory activity and the mean value for normal subjects was in excess of +2SD, was 42/50 for the inoperable and 24/33 for the operable group. The EA-rosette inhibition showed the highest frequency in anaplastic carcinoma, followed in order of succession, by adenocellular and planocellular carcinoma, it being rarest in microcellular carcinoma. In survival there was no significant difference between the EA-rosette inhibitors of the inoperable group, while the proportion of patients who were still alive at the time of completion of the assays was found to be lower among the non-inhibitors than among the inhibitors. This may be connected with the high proportion of microcellular type tumour in the negative group (4 out of 9). Successful removal of the tumour was followed by a decline of EA-rosette inhibitory activity in 14 of 17 cases. On the other hand, in 3 inoperable cases the inhibitory activity increased postoperatively.",
author = "B. Fekete and L. Sachno and I. Forrai and A. Pal",
year = "1981",
language = "English",
volume = "38",
pages = "235--243",
journal = "Acta Medica Academiae Scientiarum Hungaricae",
issn = "0001-5989",
publisher = "Akademiai Kiado",
number = "3",

}

TY - JOUR

T1 - The erythrocyte antibody-(EA)-rosette method for the demonstration of inhibitory factors binding to the lymphocyte IgG-Fc receptors in the sera of lung cancer patients

AU - Fekete, B.

AU - Sachno, L.

AU - Forrai, I.

AU - Pal, A.

PY - 1981

Y1 - 1981

N2 - Fc-inhibitory activity was demonstrated by the EA-rosette method in sera of patients with lung cancer. The sera were found to produce a significant rosette inhibition at end concentrations as low as 4%. Results obtained with sera from normal subjects as well as from patients with chronic bronchitis, were significantly different. Mean rosette inhibitory activity was significantly higher in the group of patients with inoperable lung cancer (50 cases) than in the operable group (33 cases). The proportion of patients in whom the difference between their EA-rosette inhibitory activity and the mean value for normal subjects was in excess of +2SD, was 42/50 for the inoperable and 24/33 for the operable group. The EA-rosette inhibition showed the highest frequency in anaplastic carcinoma, followed in order of succession, by adenocellular and planocellular carcinoma, it being rarest in microcellular carcinoma. In survival there was no significant difference between the EA-rosette inhibitors of the inoperable group, while the proportion of patients who were still alive at the time of completion of the assays was found to be lower among the non-inhibitors than among the inhibitors. This may be connected with the high proportion of microcellular type tumour in the negative group (4 out of 9). Successful removal of the tumour was followed by a decline of EA-rosette inhibitory activity in 14 of 17 cases. On the other hand, in 3 inoperable cases the inhibitory activity increased postoperatively.

AB - Fc-inhibitory activity was demonstrated by the EA-rosette method in sera of patients with lung cancer. The sera were found to produce a significant rosette inhibition at end concentrations as low as 4%. Results obtained with sera from normal subjects as well as from patients with chronic bronchitis, were significantly different. Mean rosette inhibitory activity was significantly higher in the group of patients with inoperable lung cancer (50 cases) than in the operable group (33 cases). The proportion of patients in whom the difference between their EA-rosette inhibitory activity and the mean value for normal subjects was in excess of +2SD, was 42/50 for the inoperable and 24/33 for the operable group. The EA-rosette inhibition showed the highest frequency in anaplastic carcinoma, followed in order of succession, by adenocellular and planocellular carcinoma, it being rarest in microcellular carcinoma. In survival there was no significant difference between the EA-rosette inhibitors of the inoperable group, while the proportion of patients who were still alive at the time of completion of the assays was found to be lower among the non-inhibitors than among the inhibitors. This may be connected with the high proportion of microcellular type tumour in the negative group (4 out of 9). Successful removal of the tumour was followed by a decline of EA-rosette inhibitory activity in 14 of 17 cases. On the other hand, in 3 inoperable cases the inhibitory activity increased postoperatively.

UR - http://www.scopus.com/inward/record.url?scp=0019724959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019724959&partnerID=8YFLogxK

M3 - Article

VL - 38

SP - 235

EP - 243

JO - Acta Medica Academiae Scientiarum Hungaricae

JF - Acta Medica Academiae Scientiarum Hungaricae

SN - 0001-5989

IS - 3

ER -